DHR

Danaher Corp

Add to Watchlist

Advanced Chart

200.560

+2.07(1.043%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

200.7424

Open

198.490

VWAP

199.72

Vol

2.96M

Mkt Cap

143.61B

Low

197.2501

Amount

591.81M

EV/EBITDA(TTM)

22.13

Total Shares

740.69M

158.02B

EV/OCF(TTM)

25.61

P/S(TTM)

6.05

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

5.99B

+3.38%

1.728

+1.06%

7.02B

+7.43%

2.383

+11.33%

6.11B

+6.39%

2.018

+7.33%

Estimates Revision

The market is revising Upward the revenue expectations for Danaher Corporation (DHR) for FY2025, with the revenue forecasts being adjusted by 0.85% over the past three months. During the same period, the stock price has changed by -0.13%.

Revenue Estimates for FY2025

Revise Upward

+0.85%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.91%

In Past 3 Month

Stock Price

Go Down

-0.13%

In Past 3 Month

17 Analyst Rating

18.57% Upside

Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 237.80 USD with a low forecast of 205.00 USD and a high forecast of 275.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

3 Hold

0 Sell

Strong Buy

18.57% Upside

Current: 200.560

Low

205.00

Averages

237.80

High

275.00

18.57% Upside

Current: 200.560

Low

205.00

Averages

237.80

High

275.00

Wells Fargo

Equal Weight

maintain

$210 -> $205

2025-07-23

Reason

Wells Fargo

Price Target

$210 -> $205

2025-07-23

maintain

Equal Weight

Reason

Wells Fargo lowered the firm's price target on Danaher to $205 from $210 and keeps an Equal Weight rating on the shares. The firm notes the company posted a solid beat/raise on EPS, while also leaving another about +15c-20c in its back pocket. Bioprocess continues to show a solid recovery, while LS should improve in the second half of the year. Pharma and China commentary was positive, Wells adds, arguing that CFO transition seems manageable.

Baird

NULL -> Outperform

maintain

$226 -> $229

2025-07-23

Reason

Baird

Price Target

$226 -> $229

2025-07-23

maintain

NULL -> Outperform

Reason

Baird raised the firm's price target on Danaher to $229 from $226 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results.

UBS

Buy

downgrade

$240 -> $225

2025-07-23

Reason

UBS

Price Target

$240 -> $225

2025-07-23

downgrade

Buy

Reason

UBS lowered the firm's price target on Danaher to $225 from $240 and keeps a Buy rating on the shares. Danaher reported an in-line Q2, but Q3 guidance was slightly below estimates, the analyst tells investors in a research note.

Evercore ISI

Outperform

maintain

$480 -> $525

2025-07-23

Reason

Evercore ISI

Price Target

$480 -> $525

2025-07-23

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Thermo Fisher (TMO) to $525 from $480 and keeps an Outperform rating on the shares. While some expected a beat following Danaher's (DHR) print, there was some concern on whether FY26 street estimates were too high, the analyst tells investors in a research note. The firm said that Thermo took the right approach by giving color on FY26/FY27, adding that it thinks FY25 has some upside potentially from China and U.S. as trends seem to be coming inline to better.

Baird

NULL -> Outperform

maintain

$225 -> $226

2025-07-18

Reason

Baird

Price Target

$225 -> $226

2025-07-18

maintain

NULL -> Outperform

Reason

Baird raised the firm's price target on Danaher to $226 from $225 and keeps an Outperform rating on the shares. The firm updated its model ahead of its Q2 report.

Scotiabank

Sung Ji Nam

Sector Perform -> Outperform

upgrade

$275

2025-07-11

Reason

Scotiabank

Sung Ji Nam

Price Target

$275

2025-07-11

upgrade

Sector Perform -> Outperform

Reason

Scotiabank analyst Sung Ji Nam upgraded Danaher to Outperform from Sector Perform with a $275 price target.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Danaher Corp (DHR.N) is 24.71, compared to its 5-year average forward P/E of 29.13. For a more detailed relative valuation and DCF analysis to assess Danaher Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

29.13

Current PE

24.71

Overvalued PE

32.58

Undervalued PE

25.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

22.78

Current EV/EBITDA

19.87

Overvalued EV/EBITDA

25.28

Undervalued EV/EBITDA

20.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

6.70

Current PS

5.65

Overvalued PS

7.45

Undervalued PS

5.95